新型内酰胺类化合物作为治疗癌症的Cbl-b抑制剂
Novel Lactams as Cbl-b Inhibitors for Treating Cancer.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2022 Sep 23;13(10):1556-1557. doi: 10.1021/acsmedchemlett.2c00413. eCollection 2022 Oct 13.
Abstract
Provided herein are novel lactams as Cbl-b inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.
摘要
本文提供了作为Cbl-b抑制剂的新型内酰胺、药物组合物、此类化合物在治疗癌症中的用途以及制备此类化合物的方法。
相似文献
1
Novel Lactams as Cbl-b Inhibitors for Treating Cancer.新型内酰胺类化合物作为治疗癌症的Cbl-b抑制剂
ACS Med Chem Lett. 2022 Sep 23;13(10):1556-1557. doi: 10.1021/acsmedchemlett.2c00413. eCollection 2022 Oct 13.
2
Novel Lactams as CBL-B Inhibitors for Treating Cancer.新型内酰胺类化合物作为用于治疗癌症的CBL - B抑制剂
ACS Med Chem Lett. 2023 Jun 21;14(7):897-898. doi: 10.1021/acsmedchemlett.3c00247. eCollection 2023 Jul 13.
3
Novel Compounds as TEAD Inhibitors for Treating Cancer.用于治疗癌症的新型TEAD抑制剂化合物
ACS Med Chem Lett. 2023 Aug 22;14(9):1152-1153. doi: 10.1021/acsmedchemlett.3c00346. eCollection 2023 Sep 14.
4
Novel Tricyclic Compounds as KRAS Inhibitors for Treating Cancer.新型三环化合物作为治疗癌症的KRAS抑制剂
ACS Med Chem Lett. 2023 Apr 26;14(5):555-556. doi: 10.1021/acsmedchemlett.3c00140. eCollection 2023 May 11.
5
Novel Pyrazoloquinoline Compounds as KRAS Inhibitors for Treating Cancer.新型吡唑并喹啉化合物作为治疗癌症的KRAS抑制剂
ACS Med Chem Lett. 2023 Jul 25;14(8):1045-1046. doi: 10.1021/acsmedchemlett.3c00300. eCollection 2023 Aug 10.
6
Novel 2,7-Naphthyridine Compounds as MASTL Inhibitors for Treating Cancer.新型2,7-萘啶化合物作为治疗癌症的MASTL抑制剂
ACS Med Chem Lett. 2024 May 1;15(6):748-749. doi: 10.1021/acsmedchemlett.4c00177. eCollection 2024 Jun 13.
7
Novel Quinoline Compounds as KRAS Inhibitors for Treating Cancer.新型喹啉化合物作为治疗癌症的KRAS抑制剂
ACS Med Chem Lett. 2023 May 26;14(6):707-708. doi: 10.1021/acsmedchemlett.3c00195. eCollection 2023 Jun 8.
8
Novel Heteroaryl Compounds as CD73 Inhibitors for Treating Cancer.新型杂芳基化合物作为用于治疗癌症的CD73抑制剂
ACS Med Chem Lett. 2024 May 31;15(6):775-776. doi: 10.1021/acsmedchemlett.4c00230. eCollection 2024 Jun 13.
9
Novel Indazole Compounds as TEAD Inhibitors for Treating Cancer.新型吲唑化合物作为治疗癌症的TEAD抑制剂
ACS Med Chem Lett. 2023 Sep 20;14(10):1334-1335. doi: 10.1021/acsmedchemlett.3c00392. eCollection 2023 Oct 12.
10
Imidazopyridine Compounds as ERK5 Inhibitors for Treating Cancer.作为用于治疗癌症的细胞外信号调节激酶5（ERK5）抑制剂的咪唑并吡啶化合物
ACS Med Chem Lett. 2024 Jun 3;15(6):777-778. doi: 10.1021/acsmedchemlett.4c00228. eCollection 2024 Jun 13.
引用本文的文献
1
Deciphering the Selectivity of CBL-B Inhibitors Using All-Atom Molecular Dynamics and Machine Learning.利用全原子分子动力学和机器学习解析CBL-B抑制剂的选择性
ACS Med Chem Lett. 2024 Jun 5;15(7):1017-1025. doi: 10.1021/acsmedchemlett.4c00047. eCollection 2024 Jul 11.
2
Quantitative evaluation of H-donating abilities of C(sp)-H bonds of nitrogen-containing heterocycles in hydrogen atom transfer reaction.含氮杂环中C(sp)-H键在氢原子转移反应中氢供体能力的定量评估。
RSC Adv. 2023 May 30;13(23):16023-16033. doi: 10.1039/d3ra02211k. eCollection 2023 May 22.
本文引用的文献
1
Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy.泛素化/去泛素化修饰的PD-1/PD-L1在癌症免疫治疗中的新作用
Genes Dis. 2022 Feb 18;10(3):848-863. doi: 10.1016/j.gendis.2022.01.002. eCollection 2023 May.
2
K63 ubiquitination in immune signaling.免疫信号转导中的 K63 泛素化
Trends Immunol. 2022 Feb;43(2):148-162. doi: 10.1016/j.it.2021.12.005. Epub 2022 Jan 13.
3
Ubiquitin ligase Cbl-b and inhibitory Cblin peptides.泛素连接酶 Cbl-b 和抑制性 Cblin 肽。
Biochim Biophys Acta Proteins Proteom. 2020 Nov;1868(11):140495. doi: 10.1016/j.bbapap.2020.140495. Epub 2020 Jul 12.
4
Regulation of immune responses by E3 ubiquitin ligase Cbl-b.E3 泛素连接酶 Cbl-b 对免疫反应的调节。
Cell Immunol. 2019 Jun;340:103878. doi: 10.1016/j.cellimm.2018.11.002. Epub 2018 Nov 7.
Zotero 插件